Arthralgia,
Osteoarthritis,
DVM,
Mayra Andrade,
Hip,
Patient,
Synovial joint,
Pain management,
ACVS,
Limp,
Quality of life,
Trial of the century,
Dog,
JW Marriott Hotels,
JW Marriott Indianapolis,
Joint,
Pain,
CCRT,
VOS,
Animal,
CCD,
Poultry farming PetVivo intends to exhibit its lead product, SPRYNG™ with OsteoCushion™ Technology.
Key Points:
- PetVivo intends to exhibit its lead product, SPRYNG™ with OsteoCushion™ Technology.
- Spryng is an intra-articular injectable veterinary medical device composed of sterilized, extra-cellular matrix microparticles.
- Such action promotes the restoration of proper joint mechanics, thereby aiding in the management of noninfectious sources of joint pain such as joint instability, degenerative joint disease and osteoarthritis.
- For more information about PetVivo Holdings, Inc. please contact [email protected] or visit https://petvivo.com/
Pain Management Forum Exhibit Details:
Location: The JW Marriott in Indianapolis, Indiana
Presentation Title: How do we Elevate Our Strategy for Managing Osteoarthritis in Pets?
PetVivo intends to exhibit its lead product, SPRYNG™ with OsteoCushion™ Technology.
Key Points:
- PetVivo intends to exhibit its lead product, SPRYNG™ with OsteoCushion™ Technology.
- Spryng is an intra-articular injectable veterinary medical device composed of sterilized, extra-cellular matrix microparticles.
- The microparticles of Spryng have been found to adsorb onto the joint synovial lining of animals and subsequently integrate with the animal’s subsynovial tissue.
- Such action promotes the restoration of proper joint mechanics, thereby aiding in the management of noninfectious sources of joint pain such as joint instability, degenerative joint disease and osteoarthritis.
PetVivo intends to exhibit its lead product, SPRYNG™ with OsteoCushion™ Technology.
Key Points:
- PetVivo intends to exhibit its lead product, SPRYNG™ with OsteoCushion™ Technology.
- Spryng is an intra-articular injectable veterinary medical device composed of sterilized, extra-cellular matrix microparticles.
- The microparticles of Spryng have been found to adsorb onto the joint synovial lining of animals and subsequently integrate with the animal’s subsynovial tissue.
- Such action promotes the restoration of proper joint mechanics, thereby aiding in the management of noninfectious sources of joint pain such as joint instability, degenerative joint disease and osteoarthritis.
CFO,
Therapy,
Animal,
Minneapolis–Saint Paul,
Financial Executives International,
CFOS,
Boy,
Bachelor,
University,
PwC,
Boy Scouts,
Phoenix (plant),
Liberal arts education,
Kiwanis,
FEI,
Athlete,
Management "We are incredibly excited to have Garry join the PetVivo management team and provide his well-recognized expertise to further the overall mission of PetVivo.” said John Lai, Chief Executive Officer of PetVivo Holdings, Inc. “Mr.
Key Points:
- "We are incredibly excited to have Garry join the PetVivo management team and provide his well-recognized expertise to further the overall mission of PetVivo.” said John Lai, Chief Executive Officer of PetVivo Holdings, Inc. “Mr.
- Mr. Lowenthal has over 25 years of extensive experience in senior operations and key finance management positions, both with private and public companies.
- Furthermore, Mr. Lowenthal has served on the national board of Financial Executives International (FEI), a premier professional association for CFOs and other senior financial executives.
- “I am thrilled to join PetVivo, a company whose technology could truly enhance the lives of companion animals,” said Mr. Lowenthal.
MINNEAPOLIS, MN, March 05, 2024 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (NASDAQ: PETV & PETVW) ("PetVivo") an emerging biomedical device company focused on the commercialization of innovative medical therapeutics for pets announced today that it will become available on March 5, 2024 at 10:00am EST under the ticker symbol “PETV” on Upstream, a MERJ Exchange market and global securities trading app. The dual listing on Upstream works to provide digital-first investors around the world with streamlined access to PetVivo shares using just an app. PetVivo’s free digital collectible NFT commemorating the dual listing is also available for all Upstream participants to claim with the claim code PETV.
Key Points:
- The dual listing on Upstream works to provide digital-first investors around the world with streamlined access to PetVivo shares using just an app.
- PetVivo’s free digital collectible NFT commemorating the dual listing is also available for all Upstream participants to claim with the claim code PETV.
- Then investors may either deposit their PetVivo shares, or fund their account with credit, debit, PayPal, USD, or USDC to buy PetVivo shares.
- Trading will commence when an existing shareholder places an offer for sale on Upstream establishing the first trade.
Retrieved on:
Thursday, February 29, 2024
Ethos,
Therapy,
VOS,
Osteoarthritis,
Quality of life,
Animal,
Dog,
Joint,
Arthralgia,
Patient,
Trial of the century Spryng™ with OsteoCuhsion™ Technology) into the coxofemoral joint of dogs with osteoarthritis.
Key Points:
- Spryng™ with OsteoCuhsion™ Technology) into the coxofemoral joint of dogs with osteoarthritis.
- The microparticles of Spryng have been found to adsorb onto the joint synovial lining of animals and subsequently integrate with the animal’s subsynovial tissue.
- The dogs enrolled in this study had been diagnosed with unilateral or bilateral coxofemoral joint osteoarthritis.
- To view the abstract of the clinical study presented at the VOS annual conference please visit the following:
Retrieved on:
Tuesday, February 27, 2024
MINNEAPOLIS, Feb. 27, 2024 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (NASDAQ: PETV & PETVW) ("PetVivo") an emerging biomedical device company focused on the commercialization of innovative medical therapeutics for pets announced today its approval to dual list its shares on Upstream, a MERJ Exchange market and global securities trading app. Trading becomes available on Upstream on March 5, 2024 at 10:00am ET under the ticker symbol “PETV.”
Key Points:
- On listing day, shareholders will receive a push notification once the shares are deposited and available for trading on Upstream.
- Details on the PetVivo listing, detailed deposit and trading instructions, and how to claim the free commemorative NFT can be found at www.petvivo.com .
- On listing day, Upstream participants will be eligible to claim a free digital collectible (NFT) memorializing the dual listing on Upstream.
- John Lai, Chief Executive Officer of PetVivo commented, “Building shareholder value is an ongoing goal of PetVivo.
Retrieved on:
Tuesday, February 13, 2024
PetVivo intends to exhibit its lead product, SPRYNG™ with OsteoCushion™ Technology, an intra-articular injectable veterinary medical device consisting of sterilized, extra-cellular matrix microparticles.
Key Points:
- PetVivo intends to exhibit its lead product, SPRYNG™ with OsteoCushion™ Technology, an intra-articular injectable veterinary medical device consisting of sterilized, extra-cellular matrix microparticles.
- The microparticles of Spryng have been found to adsorb onto the joint synovial lining of animals and subsequently integrate with the animal’s subsynovial tissue.
- WVC is the largest veterinary conference that services the western part of the United States, and normally plays host to more than 15,000+ participants including many of the top industry professionals.
- “We are incredibly excited to participate in this year’s Western Veterinary Conference.
Retrieved on:
Monday, February 12, 2024
Conference call,
Expense,
EDINA,
Marketing,
Average cost,
Animal,
Sale,
MWI,
Nine Months,
Webcast,
Three Months,
Research,
Cryptocurrency EDINA, MN, Feb. 12, 2024 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (Nasdaq: PETV), an emerging biomedical device company focused on the commercialization of innovative medical therapeutics for animals, announces financial results for the three months ended December 31, 2023 (“third quarter of 2024”).
Key Points:
- Conference call begins at 4:00 p.m. Central time today
EDINA, MN, Feb. 12, 2024 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (Nasdaq: PETV), an emerging biomedical device company focused on the commercialization of innovative medical therapeutics for animals, announces financial results for the three months ended December 31, 2023 (“third quarter of 2024”).
- “We are excited about the progress the Company has made this past quarter, including the addition of Covetrus North America, LLC.
- (Covetrus), to distribute our products beginning in January 2024,” said John Lai, Chief Executive Officer of PetVivo Holdings, Inc.
- Cost of sales were $183,087 and $223,687 for the three months ended December 31, 2023 and 2022, respectively.
Retrieved on:
Wednesday, February 7, 2024
Trial of the century,
Therapy,
Limp,
Safety,
Joint,
Pain,
Shoulder,
Synovial joint,
Animal,
Osteoarthritis,
Cat,
Arthralgia,
Hip,
Elbow Spryng™ with OsteoCushion™ Technology) into the joints of cats.
Key Points:
- Spryng™ with OsteoCushion™ Technology) into the joints of cats.
- The microparticles of Spryng have been found to adsorb onto the joint synovial lining of animals and subsequently integrate with the animal’s subsynovial tissue.
- Such action promotes the restoration of proper joint mechanics, thereby aiding in the management of noninfectious sources of joint pain such as joint instability, degenerative joint disease and osteoarthritis.
- The data provided demonstrated the excellent safety profile of Spryng when injected IA into 40 joints (10 each, shoulder, hip, elbow, stifle) across 10 individual cats.
